New nanofiltration membranes were prepared by non-solvent-induced phase inversion from a PVDF/DMF/water system. The effect of exposure time before coagulation on the membrane characteristics (morphology, thickness, overall porosity, tensile strength) was investigated. PVDF membrane prepared at a fixed exposure time of 45s (PF45) was further plasma surface modified (RF 13.56 MHz) (PF45psm), introducing amino groups on the membrane. The performances of PF45, PF45psm and of a commercial nanofiltration membrane (N30F) were tested in the removal of two dyes from aqueous solution, characterized by different charge and molecular weight (congo red and methylene blue). The observed rejections depended more on the charge of the compound than on their molecular weights and results were optimized for the plasma modified membrane (PF45psm) with respect to unmodified (PF45) and commercial N30F membranes. In particular, methylene blue was retained for 100% by PF45psm with a relative flux of 65% compared to 38% of rejection and 59% of relative flux observed for N30F.

Frontiers in ImmunologyQ2 · MEDICINE

P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine

Q2 · MEDICINE

ArticleOA

Author: Arevalo, Myriam ; Tanner, Marcel ; Bikorimana, Jean-Pierre ; Ayadi, Imen ; Agnolon, Valentina ; Spertini, François ; Audran, Régine ; Diakité, Mahamadou ; Nebie, Issa ; Balam, Saidou ; Corradin, Giampietro ; Herrera, Socrates ; Felger, Ingrid

Over the last four decades, significant efforts have been invested to develop vaccines against malaria. Although most efforts are focused on the development of P. falciparum vaccines, the current availability of the parasite genomes, bioinformatics tools, and high throughput systems for both recombinant and synthetic antigen production have helped to accelerate vaccine development against the P. vivax parasite. We have previously in silico identified several P. falciparum and P. vivax proteins containing α-helical coiled-coil motifs that represent novel putative antigens for vaccine development since they are highly immunogenic and have been associated with protection in many in vitro functional assays. Here, we selected five pairs of P. falciparum and P. vivax orthologous peptides to assess their sero-reactivity using plasma samples collected in P. falciparum- endemic African countries. Pf-Pv cross-reactivity was also investigated. The pairs Pf27/Pv27, Pf43/Pv43, and Pf45/Pv45 resulted to be the most promising candidates for a cross-protective vaccine because they showed a high degree of recognition in direct and competition ELISA assays and cross-reactivity with their respective ortholog. The recognition of P. vivax peptides by plasma of P. falciparum infected individuals indicates the existence of a high degree of cross-reactivity between these two Plasmodium species. The design of longer polypeptides combining these epitopes will allow the assessment of their immunogenicity and protective efficacy in animal models.

100 Deals associated with PF-045

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Scabies	Phase 2	Honduras	Mylan, Inc.	01 Apr 2014
Scabies	Phase 2	Puerto Rico	Mylan, Inc.	01 Apr 2014
Scabies	Phase 2	United States	Mylan, Inc.	01 Apr 2014
Scabies	Phase 2	Dominican Republic	Mylan, Inc.	01 Apr 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

PF-045

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation